Oruka Therapeutics (NASDAQ:ORKA) Sets New 1-Year High – Here’s What Happened

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $98.44 and last traded at $97.86, with a volume of 1439128 shares traded. The stock had previously closed at $88.07.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ORKA shares. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a report on Thursday, April 30th. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 23rd. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Trading Down 1.4%

The company’s 50-day simple moving average is $78.73 and its 200 day simple moving average is $57.77. The stock has a market cap of $5.82 billion, a P/E ratio of -49.75 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. Research analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the completion of the sale, the director owned 38,743 shares of the company’s stock, valued at approximately $2,716,271.73. This trade represents a 24.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 188,406 shares of company stock worth $12,019,683. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ORKA. Royal Bank of Canada raised its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the period. Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics in the fourth quarter valued at approximately $37,000. PNC Financial Services Group Inc. purchased a new position in Oruka Therapeutics during the third quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd bought a new stake in Oruka Therapeutics during the 4th quarter worth approximately $67,000. Finally, Russell Investments Group Ltd. purchased a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $43,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.